Galectin-3和CD44v6的表达与前列腺癌转移及预后的关系

目的：探讨Galectin-3和CD44v6蛋白表达与前列腺癌（PCa）临床病理特征和预后的关系。方法：应用免疫组织化学技术检测45例PCa、25例PIN和20例BPH组织中Galectin-3和CD44v6蛋白表达,并结合肿瘤的病理学行为和临床随访资料进行分析。结果：在PCa组织中,Galectin-3和CD44v6阳性表达率分别为（82．2±59．5）％、（75．6±24．0）％,均显著高于PIN和BPH组织（P〈0．05）。Galeetin-3和CD44v6表达与肿瘤分化程度、周围淋巴结转移、远处转移、预后密切相关（P〈0．05）。Galectin-3和CD44v6蛋白表达呈显著正相关（r=0．412,P==0．005）。结论：Galectin-3和CD44v6蛋白表达与PCa发生、转移和患者生存期密切相关,联合检测可以对PCa的发生、发展、预后及药物治疗提供重要依据。     

Increased expression of CD44 in hypertrophied ligamentum flavum and relevance of splice variants CD44v5 and CD44v6

Background  

The most common spinal disorder in the elderly is lumbar spinal stenosis (LSS), which results in part from ligamentum flavum (LF) hypertrophy. Although prior histologic and immunochemical studies have been performed in this area, the pathophysiology of loss of elasticity and hypertrophy is not completely understood. The purpose of this immunohistological study is to elucidate the role of CD44 and its splice variants CD44v5 and CD44v6 in the hypertrophied LF obtained from patients with lumbar spinal stenosis (LSS).     

CD44H and the isoforms CD44v5 and CD44v6 in the synovial fluid of the osteoarthritic human knee joint

OBJECTIVE: To determine whether the concentrations of CD44H and v5 and v6 in the synovial fluid are correlated with the presence of accompanying synovitis in the osteoarthritic joint and with the grade of osteoarthritis. DESIGN: Using antero-posterior and lateral X-rays of the knee joint and patellar view of 46 patients were graded with the Kellgren & Lawrence scale. Synovial fluid from these patients with different grades of primary osteoarthritis of the knee joint with and without synovial inflammation (synovitis) was collected during surgical procedures. A horseradish peroxidase conjugated anti-CD44H-, anti-sCD44v5- or anti-sCD44v6-antibody was added and labeled with tetramethylbenzidine. The absorbance was measured at wavelengths of 450/620 nm. Regression analysis was performed and the statistical significance was assessed, using the Student t-test for unequal variance. RESULTS: CD44H and v5 and v6 were detected in the synovial fluid of all 46 patients. Osteoarthritic patients with synovial inflammation showed significantly higher levels of CD44H and v6, but not v5, than osteoarthritic patients without synovial inflammation. With progression of osteoarthritis from Kellgren grade II to III, CD44v5 decreased significantly. All other isoform concentrations remained statistically unchanged. CONCLUSIONS: CD44H and the isoforms v5 and v6 were present in the synovial fluid of osteoarthritic patients. Their concentrations do not reflect the osteoarthritic stage in the Kellgren grading scale. CD44H and CD44v6, but not CD44v5, are significantly up-regulated in osteoarthritic synovial inflammation.     

恶性脑肿瘤中CD44内含子9及CD44v6mRNA的表达水平及临床意义

目的 了解CD44内含子9、CD44v6mRNA在恶性脑肿瘤中的表达水平及临床意义。方法 应用RT－PCR技术检测28例恶性脑膜瘤,25例脑神经胶质瘤及20例脑瘤旁组织中CD44内含子9、CD44v6mRNA的表达并对mRNA含量进行半定量分析。结果 CD44v6mNRNA在恶性脑膜瘤和脑神经胶质瘤的阳性表达率分别为92．9％（26／28）和88．0％（22／25）,明显于高瘤旁组织的5％（1／20）,差异有非常显著性意义（P＜0．01）,前二者相对含量（mass）值明显高于瘤旁组织。恶性脑膜瘤和脑神经胶质瘤CD44内含子9mRNA表达水平明显高于瘤旁组织（P＜0．01）。结论 CD44内含子9、CD44v6mRNA内含子9mRNA表达水平明显高于瘤旁组织（P＜0．01）。结论 CD44内含子9、CD44v6mRNA对辅助诊断恶性脑肿瘤有一定的意义。     

膀胱尿路上皮细胞癌CD44s和CD44v8蛋白的表达及临床意义

目的：探讨CD44s和CD44v8蛋白在膀胱尿路上皮细胞癌中的表达及其与临床病理的相关性。方法：应用免疫组织化学技术检测60例膀胱尿路上皮细胞癌和10例正常膀胱黏膜CD44s和CD44v8蛋白的表达。结果：CD44s在正常膀胱黏膜及膀胱尿路上皮细胞癌中都有不同程度的表达,60例膀胱尿路上皮细胞癌中阳性表达是25例（41．7％）,阳性表达与肿瘤的病理分级,TNM分期相关,而与肿瘤的复发,数量无相关性,且分型表达与病理分级相关。CD44v8在正常膀胱黏膜无表达,60例膀胱尿路上皮细胞癌中阳性表达是28例（46．7％）,与肿瘤的病理分级,TNM分期相关,而与肿瘤的复发,数量无相关性。结论：BTCC组织中CD44s和CD44v8有’相关性,可作为判断膀胱尿路上皮细胞癌分级,分期的一个参考指标,联合检测可以可提高判断的敏感性。     

Determination of prognosis in patients with prostate cancer treated with radical prostatectomy: prognostic value of CD44v6 score

PURPOSE: A third of the patients treated with radical prostatectomy experience progression even when tumors are confined pathologically to the prostate. CD44 may be a promising prognostic marker for determining malignant potential. However, there has not been a standard scoring system because of its heterogeneous staining pattern. Thus, we developed an objective scoring system to evaluate reliably CD44v6 (Bender Medsystems, Vienna, Austria) as a prognostic marker for prostate cancer. MATERIALS AND METHODS: A total of 22 patients with metastatic stage pT3bN0M0 or any pTN1M0 disease and 18 with nonmetastatic disease less than stage pT3bN0M0 were selected from a well examined group of 114 who underwent radical retropubic prostatectomy. Mean followup was 33 months (range 4 to 78). A combined CD44v6 score was determined by adding the scores of the primary and secondary areas. CD44v6 expression in terms of the CD44v6 score in primary and metastatic tissues was examined. The relationships of CD44v6 expression with pathological stage, progression and PSA-free survival were also evaluated. The prognostic value of the CD44v6 score for progression was analyzed by multivariate analysis. RESULTS: Progression in the metastatic group was significantly higher than in the nonmetastatic group (p <0.0001). CD44v6 expression of the primary tumors differed significantly in the 2 groups (p = 0.014). The CD44v6 score in primary tumor tissues inversely correlated with pathological stage (p = 0.004) and progression (p = 0.035), and positively correlated with PSA-free survival (p = 0.041). Furthermore, patients in the nonmetastatic group with a CD44v6 score of greater than 75 (cutoff value) had a significantly better prognosis (log rank test p = 0.0022), while those with a CD44v6 score of less than 75 had a prognosis similar to those in the metastatic group. On multivariate analysis pathological stage and surgical margin positivity were independent factors for progression but the CD44v6 score was not. CONCLUSIONS: According to our results the suggested CD44v6 score system is useful. A CD44v6 score of less than 75 may be a predictor of poor prognosis in the nonmetastatic group and this property may have potential application for planning adjuvant therapy.     

膀胱尿路上皮细胞癌CD44v6和CD44v8蛋白的表达及临床意义

目的 探讨C044v6和CD44v8蛋白在膀胱尿路上皮细胞癌中的表达及其与临床病理的相关性.方法 应用免疫组织化学技术检测60例膀胱尿路上皮细胞癌和10例正常膀胱粘膜CD44v6和CD44v8蛋白的表达.结果 CD44v6在10例正常膀胱粘膜无表达,60例膀胱尿路上皮细胞癌中阳性表达23例(38.3%),阳性表达与肿瘤的病理分级,TNM分期相关.CD44v8在10例正常膀胱粘膜无表达,60例膀胱尿路上皮细胞癌中阳性表达是29例(48.3%),阳性表达与肿瘤的病理分级,TNM分期相关.结论 膀胱尿路上皮细胞癌组织中CD44v6和CD44v8有相关性,可作为判断膀胱尿路上皮细胞癌分级,分期的一个参考指标,联合检测可以可提高判断的敏感性.     

Expression profile of CD44s,CD44v6, and CD44v10 in localized prostate cancer: Effect on prognostic outcomes following radical prostatectomy

ObjectivesTo investigate the expression of CD44 standard form (CD44s) and 2 major variant exons (CD44v6 and CD44v10) in localized prostate cancer (PC) to determine the prognostic significance of these markers following radical prostatectomy (RP).Materials and methodsExpression levels of CD44s, CD44v6, and CD44v10 in RP specimens from 160 consecutive patients with clinically localized PC were evaluated by immunohistochemical staining.ResultsOf these 3 markers, expression level of CD44v6 was closely associated with several conventional prognostic factors. Univariate analysis identified CD44v6 expression in addition to serum prostate-specific antigen level, Gleason score, seminal vesicle invasion, and surgical margin status as significant predictors for biochemical recurrence (BR). Of these significant factors, CD44v6 expression, serum prostate-specific antigen level, and surgical margin status appeared to be independently associated with BR on multivariate analysis. We observed significant differences in BR-free survival according to the positive numbers of these 3 independent factors; i.e., BR occurred in 0 (0%) of 42 patients who had negative results for risk factors, 9 (16.7%) of 54 who had positive results for 1 risk factor, and 31 (48.4%) of 64 who had positive results for 2 or 3 risk factors.ConclusionsAssessment of the expression levels of CD44v6 in RP specimens in addition to conventional prognostic parameters would contribute to the accurate prediction of the biochemical outcome in patients with localized PC who underwent RP.     

CD44 与膀胱肿瘤的研究现状

大量的研究表明,CD44 及其变异体在膀胱肿瘤的发生和发展过程中起着重要的作用,其研究近年来又取得了一些新的进展,本文就CD44 与膀胱肿瘤的研究最新进展作一综述.     

CD44 与膀胱肿瘤的研究现状

大量的研究表明,CD44 及其变异体在膀胱肿瘤的发生和发展过程中起着重要的作用,其研究近年来又取得了一些新的进展,本文就CD44 与膀胱肿瘤的研究最新进展作一综述.     

CD44 与膀胱肿瘤的研究现状

大量的研究表明,CD44 及其变异体在膀胱肿瘤的发生和发展过程中起着重要的作用,其研究近年来又取得了一些新的进展,本文就CD44 与膀胱肿瘤的研究最新进展作一综述.     

CD44 与膀胱肿瘤的研究现状

大量的研究表明,CD44 及其变异体在膀胱肿瘤的发生和发展过程中起着重要的作用,其研究近年来又取得了一些新的进展,本文就CD44 与膀胱肿瘤的研究最新进展作一综述.     

CD44 与膀胱肿瘤的研究现状

大量的研究表明,CD44 及其变异体在膀胱肿瘤的发生和发展过程中起着重要的作用,其研究近年来又取得了一些新的进展,本文就CD44 与膀胱肿瘤的研究最新进展作一综述.     

CD44 与膀胱肿瘤的研究现状

大量的研究表明,CD44 及其变异体在膀胱肿瘤的发生和发展过程中起着重要的作用,其研究近年来又取得了一些新的进展,本文就CD44 与膀胱肿瘤的研究最新进展作一综述.     

CD44 与膀胱肿瘤的研究现状

大量的研究表明,CD44 及其变异体在膀胱肿瘤的发生和发展过程中起着重要的作用,其研究近年来又取得了一些新的进展,本文就CD44 与膀胱肿瘤的研究最新进展作一综述.     

CD44 与膀胱肿瘤的研究现状

大量的研究表明,CD44 及其变异体在膀胱肿瘤的发生和发展过程中起着重要的作用,其研究近年来又取得了一些新的进展,本文就CD44 与膀胱肿瘤的研究最新进展作一综述.     

CD44 与膀胱肿瘤的研究现状

大量的研究表明,CD44 及其变异体在膀胱肿瘤的发生和发展过程中起着重要的作用,其研究近年来又取得了一些新的进展,本文就CD44 与膀胱肿瘤的研究最新进展作一综述.     

CD44 与膀胱肿瘤的研究现状

大量的研究表明,CD44 及其变异体在膀胱肿瘤的发生和发展过程中起着重要的作用,其研究近年来又取得了一些新的进展,本文就CD44 与膀胱肿瘤的研究最新进展作一综述.